Avantor, Inc. (NYSE:AVTR) Short Interest Update

Avantor, Inc. (NYSE:AVTR) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 33,090,000 shares, a drop of 7.9% from the September 30th total of 35,910,000 shares. Based on an average daily volume of 7,300,000 shares, the short-interest ratio is currently 4.5 days.

Insider Transactions at Avantor

In related news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Versant Capital Management Inc grew its stake in shares of Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after purchasing an additional 1,102 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Avantor by 1,830.3% in the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after buying an additional 1,391 shares in the last quarter. UMB Bank n.a. acquired a new stake in shares of Avantor during the 3rd quarter valued at $49,000. Nisa Investment Advisors LLC lifted its position in shares of Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after acquiring an additional 835 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after acquiring an additional 1,285 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Stock Performance

Shares of AVTR traded down $0.09 during trading hours on Thursday, reaching $22.37. 5,943,940 shares of the company’s stock traded hands, compared to its average volume of 6,441,773. The firm has a market capitalization of $15.20 billion, a price-to-earnings ratio of 57.36, a P/E/G ratio of 2.93 and a beta of 1.33. The business’s fifty day simple moving average is $25.26 and its two-hundred day simple moving average is $24.19. Avantor has a twelve month low of $17.06 and a twelve month high of $28.00. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Morgan Stanley raised their price objective on Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. UBS Group decreased their price target on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, October 8th. Barclays decreased their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Robert W. Baird decreased their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Wells Fargo & Company reduced their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.57.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.